Predictive Technology Group Inc (PRED)

[Marty Byrd]

Reported $48K Revenue for Diagnostics & Therapeutics (page 51). Possibly starting to charge for the test kits. They have been giving them away over the past year.

Top page 36 - During the twelve months ending June 30, 2019 we launched two new molecular diagnostic tests. PGxPLUS+ was launched in the 2nd quarter with consecutive quarter over quarter volume growth. The PGxPLUS+ test is currently being used to help physicians assess medication selection for patients with chronic pain. In the fourth quarter we grew our pharmacogenomic test volume (PGxPLUS+) 86% compared to the previous quarter. In the third quarter, we signed an agreement with Houston Fertility Institute (HFI) to continue the clinical evidence development of the ARTguide genetic test for Reproductive Endocrinologists. A priority of the agreement will be to establish clinical utility data demonstrating improved outcomes from the utilization of ARTguide for patients receiving fertility treatment. In the fourth quarter we increased ARTguide test volume 25% compared to the preceding quarter.